with a mean increase of 8 points) and tirzepatide (SUMMIT), appears to be greater than what has been reported for other HFpEF trials investigating the benefits of angiotensin receptorneprilysin inhibitor (Paragon-HF), sodiumglucose cotransporter 2 inhibitors (EMPEROR-Preserved, DELIVER) and spironolactone (TOPCAT)
We dont put a limit in terms of minimum clinically relevant effect size for PFS, as this depends on the balance with the risks. Tafuri adds: It may be time for the oncology community and regulatory agencies to take a hard look at PFS and reflect on whether this can be used as a primary efficacy endpoint in a specific oncology setting. It may be time to take a hard look at whether PFS can be used as a primary efficacy endpoint in a specific setting As Hartmann says, this can also be seen as part of a move to incorporate patient groups much more in evaluating what factors are important in the benefitrisk assessment of drugs
Dont Eat Large, Rich Meals When youre on a GLP-1 medication, food that is eaten stays in every part of the gastrointestinal tract for longer, says Jessica Cutler, MD, a weight loss surgeon with The Maryland Bariatric Center at Mercy Medical Center in Baltimore
The slow digestion of these foods can help keep your blood sugar levels steady and could motivate your body to produce more GLP-1
But its a little more complicated than a simple deficiency